SNV4818 is an oral drug and is presently being assessed in an ongoing Phase I/II trial for breast cancer.
J&J’s Icotyde will take on AbbVie’s blockbuster injectable Skyrizi as analysts forecast a blockbuster future for the pill.
The technology is designed to simplify the bio-separation process while reducing manufacturing costs.
The investment will fund the Phase I/Ib study of CGX-926 for MC4R-deficient genetic obesity in healthy subjects and patients.
The streamlined framework is part of the UK Government’s plans to ensure the life sciences sector reaches its full potential.
An expert involved in the first successful gene therapy trial for Huntington's Disease discusses the trial results and challenges with the FDA.
